地尔硫对冠心病患者经皮冠状动脉介入治疗术后近期主要不良心血管事件的影响  

The effect of Diitiazem on the major adverse cardiac events after percntaneous coronary intervention

作　　者：唐义信[1] 朱灵萍 孙权[2] 裴志芳[1] 童霄羽 罗瑛[2] 

机构地区：[1]中南大学湘雅医院心血管内科,长沙410078 [2]中南大学湘雅医院老年病科,长沙410078

出　　处：《中华老年医学杂志》2015年第9期959-961,共3页Chinese Journal of Geriatrics

基　　金：湖南省自然科学基金（2014SK3014）

摘　　要：目的观察地尔硫革对冠心病患者经皮冠状动脉介入治疗（PCI）术后6个月内主要不良心血管事件（MAcE）的影响。方法冠心病PCI术后的患者192例，随机分为地尔硫革治疗组（治疗组）101例和常规治疗组（对照组）91例，观察两组患者术前、术后24h超敏C反应蛋白（hs—CRP）的变化水平及6个月内MACE的发生。结果治疗组和对照组患者PCI术后hs—CRP分别为（6．59±1．45）mg／L、（8．37±1．82）mg／L，较术前（4．11±0．82）mg／L、（4．25±0．67）mg／L明显升高（t=14．962、20．265，均P=0．000），但与对照组比较，治疗组术后hs—CRP升高幅度较低（t=7．529，P=0．000）；治疗组6个月内MACE的发生人数为9例，较对照组23例低，差异有统计学意义（χ^2=9．229，P=0．002）。结论PCI术后予以地尔硫革治疗能降低6个月内MACE的发生。[Abstract] Objective To detect the impact of Diltiazem on the major adverse cardiac events （MACE） in six months after percutaneous coronary intervention （PCI）. Methods A total of 192 patients after PCI with coronary atherosclerotic heart disease were enrolled in this study. The patients were randomly divided into Diltiazem therapy group （101 patients） and non-Diltiazem therapy group （91 patients）. The high-sensitivity C-reactive protein （hs-CRP） was assessed before and 24 h after PCI, and the incidence of Major adverse cardiovascular events（MACEs） were assessed at the sixth month after PCI. Results Compared with before PCI, hs-CRP level increased significantly in both group after PCI （P〈0.01）, but hs-CRP level was lower in Diltiazem therapy group than in non- Diltiazem therapy group （P〈0.05）. Compared with non-Diltiazem therapy group, there was lower incidence of MACEs during six months follow-up in Diltiazem therapy group. Conclusions Diltiazem can decrease the incidence of MACEs during six months after PCI.

关 键 词：冠心病 血管成形术 经腔 经皮冠状动脉 钙通道阻滞剂 C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]